- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and moreGSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncologySTAT · 1mo ago↗ source
- Dexcom RCT suggests CGM benefits for broad diabetes populationIn this edition of STAT Health Tech: Dexcom's CGM trial, udpates from Apple's annual developers' conference, and wearables.STAT · 1mo ago↗ source
- STAT+: NIH staffers published a letter of dissent a year ago. They feel it’s been ignoredIn a report published on the first anniversary of the Bethesda Declaration, 71 staffers write that they feel NIH leadership “largely ignored" their concerns.